Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Due to the biological heterogeneity, 60%–70% of patients with major depressive disorder (MDD) do not respond to or achieve remission from first‐line antidepressants. Predicting neuroimaging biomarkers for early antidepressant treatment could guide initial antidepressant therapy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>To assess for neuroimaging biomarkers for antidepressant selection in early antidepressant treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Study Type</h3><p>Prospective.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Subjects</h3><p>A total of 85 MDD patients from the major site and 33 MDD patients from an out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Field Strength/Sequence</h3><p>A 3.0 T, T1‐weighted imaging using a magnetization‐prepared rapid acquisition gradient‐echo sequence and diffusion tensor imaging (DTI) using an echo‐planar sequence.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Assessment</h3><p>Baseline DTI data of patients who achieved early improvement after 2‐weeks of antidepressant treatment (selective serotonin reuptake inhibitors [SSRI] or serotonin‐norepinephrine reuptake inhibitors [SNRI]) were analyzed. An ensemble model was constructed using data from the major site and then applied to assess the early response of patients at the out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Statistical Tests</h3><p>Support vector machine combined with leave‐one‐out cross‐validation were applied to construct the whole model from individual base models from different brain regions. Discriminative biomarkers were evaluated by calculating the changes in sensitivity and specificity obtained when removing a single base model from the whole model, the base model being removed changing in each run.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Training performance over MDD patients at the major site achieved 75% accuracy while performance with accuracy of 70% was achieved in the out‐of‐sample test site. Assessing sensitivity and specificity changes following the removal of single base models from the prominent model highlighted the functions of two neural circuitries: SSRI‐related emotion regulation circuitry, centered on the hippocampus (sensitivity changes: 10%) and amygdala (sensitivity changes: 11%); and SNRI‐related emotion and reward circuitry, centered on the putamen (specificity changes: 8%) and orbital part of superior frontal gyrus (specificity changes: 12%).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Data Conclusion</h3><p>These findings support future research on clinical antidepressant selection for MDD.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Evidence Level</h3><p>1</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Technical Efficacy</h3><p>Stage 2</p></section>

Combination of Spontaneous Regional Brain Activity and HTR1A/1B DNA Methylation to Predict Early Responses to Antidepressant Treatments in MDD

Prediction of Early Antidepressant Efficacy in Patients with Major Depressive Disorder Based on Multidimensional Features of Rs-Fmri and P11 Gene DNA Methylation

Combined HTR1A/1B Methylation and Human Functional Connectome to Recognize Patients with MDD

Influence and interaction of resting state functional magnetic resonance and tryptophan hydroxylase-2 methylation on short-term antidepressant drug response

Predicting Neuroimaging Biomarkers for Antidepressant Selection in Early Treatment of Depression

Identification of multimodal brain imaging biomarkers in first-episode drugs-naive major depressive disorder through a multi-site large-scale MRI consortium data

Sub-hubs of Baseline Functional Brain Networks Are Related to Early Improvement Following Two-Week Pharmacological Therapy for Major Depressive Disorder.

Ensemble Learning for Early‐Response Prediction of Antidepressant Treatment in Major Depressive Disorder

Local and large-scale resting-state oscillatory dysfunctions for early antidepressant response prediction in major depressive disorder

Connectome-based models can predict early symptom improvement in major depressive disorder

Distinct MRI-based functional and structural connectivity for antidepressant response prediction in major depressive disorder

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Predict Value of Functional Topological Features for Early Response to Antidepressant Treatment in Major Depressive Disorder

Dopamine Multilocus Genetic Profile, Spontaneous Activity of Left Superior Temporal Gyrus, and Early Therapeutic Effect in Major Depressive Disorder

Predicting Treatment Selections for Individuals with Major Depressive Disorder According to Functional Connectivity Subgroups

An Investigation into the Association Between Dopamine Receptor D1 Multilocus Genetic Variation, Multiparametric Magnetic Resonance Imaging, and Antidepressant Treatment

Distinct Features of Cerebral Blood Flow and Spontaneous Neural Activity as Integrated Predictors of Early Response to Antidepressants.

Prognostic prediction of therapeutic response in depression using high-field MR imaging.

Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder